Drugs / Elecoglipron
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07723833 | Jul → Nov 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07534592 | Apr → Aug 2026 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06579092 | Oct 2024 → Nov 2025 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07761117 | Aug 2026 → Sep 2029 expected | heart failure | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07775404 | Aug 2026 → Apr 2028 expected | obesity disorder | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07753993 | Aug 2026 → Oct 2030 expected | chronic kidney disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07662044 | Jul 2026 → Jul 2028 expected | type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07664553 | Jul 2026 → May 2028 expected | type 2 diabetes mellitus | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07662213 | Jul 2026 → May 2028 expected | type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07662135 | Jul 2026 → Jul 2028 expected | chronic kidney disease, type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07662109 | Jul 2026 → Jul 2028 expected | type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07667803 | Jun 2026 → Jul 2028 expected | — | AstraZeneca | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | AstraZeneca | Results Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio astrazeneca.com ↗
Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo. |
| 2026-02-10 | Eccogene | Results Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China eccogene.com ↗
The results demonstrated a safety and tolerability profile consistent with the GLP-1 receptor agonist (GLP-1RA) class. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elecoglipron | “Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction” PMID 42259337 ↗ Jun 2026 |
| Known as | AZD5004 | “Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction” PMID 42259337 ↗ Jun 2026 |
| Action | Activate | “GLP-1) receptor agonist” PMID 42259337 ↗ Jun 2026 |
| Route | Oral | “Elecoglipron was administered as oral once-daily tablets” PMID 42259337 ↗ Jun 2026 |